In summary, BMSCs isolated from intracerebral xenograft GSC tumors were found to undergo malignant transformation, and the suppression of miR-146a-5p was found to promote this process by activating the oncogene HNRNPD. These results suggest that targeted glioma therapies using MSCs as cellular carriers should be used cautiously, due to the risk that MSCs will undergo malignant transformation in the glioma microenvironment. Here, HNRNPD is linked to glioma.